US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors. (2nd June 2015)

• Record Type: Journal Article
• Authors: Valentino, L. A.; Kempton, C. L.; Kruse‐Jarres, R.; Mathew, P.; Meeks, S. L.; Reiss, U. M.; the International Immune Tolerance Induction Study Investigators
• Is Part Of: Haemophilia. Volume 21:Number 5(2015:Sep.)
• Page Start: 559
• Page End: 567
• Publication Date: 2015-06-02
• Subjects: Hemophilia -- Periodicals; 616.1572005
• DOI: 10.1111/hae.12730
• Languages: English
• ISSNs: 1351-8216

Abstract

<abstract abstract-type="main" id="hae12730-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="hae12730-sec-0001" sec-type="section"> <title>Introduction</title> <p>The development of anti‐factor VIII (FVIII) antibodies (inhibitors) is the most serious treatment‐related complication in patients with hemophilia A, rendering standard replacement therapy ineffective, heightening the risk for uncontrollable bleeding and morbidity, decreasing quality of life, and increasing healthcare costs.</p> </sec> <sec id="hae12730-sec-0002" sec-type="section"> <title>Aim</title> <p>Formulate evidence‐based guidelines for optimizing immune tolerance induction (ITI) in patients with hemophilia A and inhibitors.</p> </sec> <sec id="hae12730-sec-0003" sec-type="section"> <title>Methods</title> <p>Results from the International ITI study and other available evidence were used to develop guidelines for ITI.</p> </sec> <sec id="hae12730-sec-0004" sec-type="section"> <title>Results</title> <p>Predictors of ITI success were identified and recommendations made for ITI with regard to candidates, timing, product, regimen, monitoring, defining success, concurrent immunomodulation, duration of treatment, and bleed management before and during ITI.</p> </sec> <sec id="hae12730-sec-0005" sec-type="section"> <title>Conclusion</title> <p>Evidence‐based recommendations to guide treatment decisions may increase the likelihood of successful inhibitor eradication and the induction of FVIII tolerance in patients with hemophilia A who develop inhibitory antibodies.</p> </sec> </abstract>